Pharnext : to host a key opinion leader symposium focused on CMT1A

Press Release

Pharnext Key Opinion Leader Symposium on

Charcot-Marie-Tooth Disease Type 1A

PARIS, France, 7:30 am, July 30 2018 (CEST) -Pharnext SA(FR0011191287 - ALPHA) a biopharmaceutical company pioneering a new approach to the development of innovative drug combinations based on big genomic data and artificial intelligence, today announced it will host a key opinion leader symposium focused on addressing unmet need in Charcot-Marie-Tooth Disease Type 1A (CMT1A) on Tuesday, July 31st at 8:30 a.m. ET in New York.

Guest speakers scheduled to present at the event include:

• • Florian P. Thomas, MD, MA, PhD, MS, Founding Chair & Professor of the Department of Neurology at Seton Hall-Hackensack-Meridian School of Medicine, Chair of the Neuroscience Institute, and Chair of the Department of Neurology at Hackensack University Medical Center

• • Allison Moore, CEO & Founder of the Hereditary Neuropathy Foundation

Additionally, Pharnext management will provide an overview of the Company's recent progress, including its ongoing pivotal Phase 3 trial of PXT3003 for the treatment of CMT1A

A live audio webcast of the event can be accessed on the Pharnext website,www.pharnext.com.An archived replay will be available for at least 30 days after the event concludes.

About Pharnext

Pharnext is an advanced clinical-stage biopharmaceutical company developing novel therapeutics for orphan and common neurodegenerative diseases that currently lack curative and/or disease-modifying treatments. Pharnext has two lead products in clinical development. PXT3003 is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. PXT864 has generated encouraging Phase 2 results in Alzheimer's disease. Pharnext has developed a new drug discovery paradigm based on big genomic data and artificial intelligence:

PLEOTHERAPY™. The Company identifies and develops synergic combinations of drugs called PLEODRUG™ offering several key advantages: efficacy, safety and robust intellectual property. The Company was founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics and is supported by a world-class scientific team.

Pharnext is listed on Euronext Growth Stock Exchange in Paris (ISIN code: FR0011191287). For more information, visithttp://www.pharnext.com/

CONTACTS:

Pharnext

René Goedkoop Chief Medical Officercontact@pharnext.com +33 (0)1 41 09 22 30

PHARNEXT | CREATING NEW SOLUTIONS

Page 2